Catalyst Program
Welcome to Broken String Biosciences
Broken String Biosciences is at the forefront of enhancing the safety and efficacy of gene editing therapies to enable transformative therapeutics to become a safe reality for patients.
About the technology
INDUCE-seq® is a game changing technology for the characterisation of genome breaks in cell & gene therapy applications.
Updates
-
Broken String Biosciences Launches Catalyst Program to Shorten Gene Editing Therapy Development by Months
BOSTON, MA and Cambridge, UK, February 6, 2025 – Broken String Biosciences (“Broken String”), a leader in advancing gene editing safety, today opened its Catalyst Early Access Program (EAP) for developers of gene-edited therapies that allow for the detection of on- and off-target edits at high resolution, in days, in their own labs. The program…
-
Broken String Biosciences appoints Laurence Reid and Brad Crutchfield to its Board of Directors
Cambridge, UK, 23 September 2024: Broken String Biosciences (“Broken String”), a genomics company enabling development of the next generation of more precise, safe, and effective cell and gene therapies, today announced the appointments of Laurence Reid, PhD, as Chairman, and Brad Crutchfield as Non-Executive Director (NED) of its Board of Directors. Bringing extensive commercial and leadership expertise to the Board, Laurence…
-
Broken String Biosciences appoints Steve Becker as Chief Commercial Officer
Appointment brings extensive experience to lead commercial operations and accelerate growth in key global markets Cambridge, UK, 24 July 2024: Broken String Biosciences (“Broken String”), a genomics company driving development of the next generation of more precise, safe, and effective cell and gene therapies, today announced it has appointed Steve Becker as Chief Commercial Officer. An experienced global life sciences executive,…
-
Broken String Biosciences and the Francis Crick Institute collaborate to advance ALS research
Partnership to expand applications of DNA break-mapping technology and advance understanding of genomic instability in development of the neurodegenerative disease amyotrophic lateral sclerosis Cambridge, UK, 7 May 2024: Broken String Biosciences (“Broken String”), a genomics company driving development of the next generation of more precise, safe, and effective cell and gene therapies, today announced it has entered a research collaboration with…
-
Broken String Biosciences appoints Gavin Burns as Vice President of Quality and Operations
Cambridge, UK, 22 November 2023: Broken String Biosciences (“Broken String”), a genomics company that has built a technology platform to drive the development of cell and gene therapies that are safer by design, today announced the appointment of Gavin Burns, PhD, as Vice President of Quality and Operations. With an extensive background leading quality assurance in…
-
Broken String Biosciences’ INDUCE-seq platform demonstrates impact of structural DNA changes on specificity of CRISPR-Cas9 gene editing
Cambridge, UK, 18 October 2023: Broken String Biosciences (“Broken String”), a genomics company building a technology platform to drive the development of cell and gene therapies that are safer by design, today announced that its INDUCE-seq™ DNA break-mapping technology had been used in a peer-reviewed research paper to characterize off-target effects of CRISPR-Cas9 gene editing…
-
Broken String Biosciences strengthens senior leadership team to accelerate product development
Cambridge, UK, 02 October 2023: Broken String Biosciences (“Broken String”), a genomics company building a technology platform to drive the development of cell and gene therapies that are safer by design, today announced the expansion of its senior leadership team with the appointment of Vincent Smith, PhD, as Chief Technology Officer. Bringing significant expertise in his…
-
Broken String Biosciences Closes $15M Series A Funding Round
Cambridge, UK, 18 September 2023: Broken String Biosciences (“Broken String”), a genomics company building a technology platform to drive the development of cell and gene therapies that are safer by design, today announced that it has closed a $15 million Series A investment round, co-led by Illumina Ventures and Mérieux Equity Partners, with contributions from…
Meet the team
Our team operates at the intersection of biology, bioinformatics and data science.
